Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy

Kaitkanoke Sirinarumitr, Shirley D. Johnston, Margaret V. Root Kustritz, Gary R. Johnston, Dipak K. Sarkar, Mushtaq A. Memon

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective - To determine the effect of the 5α-reductase inhibitor finasteride on prostatic diameter and volume, semen quality, and serum dihydrotestosterone (DHT) and testosterone concentrations in dogs with spontaneous benign prostatic hypertrophy (BPH). Design - Double-blind placebo-controlled trial. Animals - 9 dogs with BPH. Procedure - Five dogs were treated with finasteride for 16 weeks (0.1 to 0.5 mg/kg [0.05 to 0.23 mg/lb] of body weight, PO, q 24 h); the other 4 received a placebo. Prostatic diameter, measured radiographically, prostatic volume, measured ultrasonographically, semen quality, and serum DHT and testosterone concentrations were evaluated before and during treatment. After receiving the placebo for 16 weeks, the 4 control dogs were treated with finasteride for 16 weeks, and evaluations were repeated. Results - Finasteride significantly decreased prostatic diameter (mean percentage decrease, 20%), prostatic volume (mean percentage decrease, 43%), and serum DHT concentration (mean percentage decrease, 58%). Finasteride decreased semen volume but did not adversely effect semen quality or serum testosterone concentration. No adverse effects were reported by owners of dogs in the study. Conclusions and Clinical Relevance - Results suggest that finasteride can be used to reduce prostatic size in dogs with BPH without adversely affecting semen quality or serum testosterone concentration.

Original languageEnglish (US)
Pages (from-to)1275-1280
Number of pages6
JournalJournal of the American Veterinary Medical Association
Volume218
Issue number8
DOIs
StatePublished - Apr 15 2001

Fingerprint

Finasteride
prostate gland
Semen Analysis
Prostatic Hyperplasia
hypertrophy
semen
Prostate
Dogs
testosterone
Testosterone
Dihydrotestosterone
dogs
placebos
Serum
Placebos
Semen
Oxidoreductases
adverse effects
Body Weight
body weight

Cite this

Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. / Sirinarumitr, Kaitkanoke; Johnston, Shirley D.; Root Kustritz, Margaret V.; Johnston, Gary R.; Sarkar, Dipak K.; Memon, Mushtaq A.

In: Journal of the American Veterinary Medical Association, Vol. 218, No. 8, 15.04.2001, p. 1275-1280.

Research output: Contribution to journalArticle

Sirinarumitr, Kaitkanoke ; Johnston, Shirley D. ; Root Kustritz, Margaret V. ; Johnston, Gary R. ; Sarkar, Dipak K. ; Memon, Mushtaq A. / Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. In: Journal of the American Veterinary Medical Association. 2001 ; Vol. 218, No. 8. pp. 1275-1280.
@article{b8a366995b534ed6bd0d2dbf585ff0a7,
title = "Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy",
abstract = "Objective - To determine the effect of the 5α-reductase inhibitor finasteride on prostatic diameter and volume, semen quality, and serum dihydrotestosterone (DHT) and testosterone concentrations in dogs with spontaneous benign prostatic hypertrophy (BPH). Design - Double-blind placebo-controlled trial. Animals - 9 dogs with BPH. Procedure - Five dogs were treated with finasteride for 16 weeks (0.1 to 0.5 mg/kg [0.05 to 0.23 mg/lb] of body weight, PO, q 24 h); the other 4 received a placebo. Prostatic diameter, measured radiographically, prostatic volume, measured ultrasonographically, semen quality, and serum DHT and testosterone concentrations were evaluated before and during treatment. After receiving the placebo for 16 weeks, the 4 control dogs were treated with finasteride for 16 weeks, and evaluations were repeated. Results - Finasteride significantly decreased prostatic diameter (mean percentage decrease, 20{\%}), prostatic volume (mean percentage decrease, 43{\%}), and serum DHT concentration (mean percentage decrease, 58{\%}). Finasteride decreased semen volume but did not adversely effect semen quality or serum testosterone concentration. No adverse effects were reported by owners of dogs in the study. Conclusions and Clinical Relevance - Results suggest that finasteride can be used to reduce prostatic size in dogs with BPH without adversely affecting semen quality or serum testosterone concentration.",
author = "Kaitkanoke Sirinarumitr and Johnston, {Shirley D.} and {Root Kustritz}, {Margaret V.} and Johnston, {Gary R.} and Sarkar, {Dipak K.} and Memon, {Mushtaq A.}",
year = "2001",
month = "4",
day = "15",
doi = "10.2460/javma.2001.218.1275",
language = "English (US)",
volume = "218",
pages = "1275--1280",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "8",

}

TY - JOUR

T1 - Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy

AU - Sirinarumitr, Kaitkanoke

AU - Johnston, Shirley D.

AU - Root Kustritz, Margaret V.

AU - Johnston, Gary R.

AU - Sarkar, Dipak K.

AU - Memon, Mushtaq A.

PY - 2001/4/15

Y1 - 2001/4/15

N2 - Objective - To determine the effect of the 5α-reductase inhibitor finasteride on prostatic diameter and volume, semen quality, and serum dihydrotestosterone (DHT) and testosterone concentrations in dogs with spontaneous benign prostatic hypertrophy (BPH). Design - Double-blind placebo-controlled trial. Animals - 9 dogs with BPH. Procedure - Five dogs were treated with finasteride for 16 weeks (0.1 to 0.5 mg/kg [0.05 to 0.23 mg/lb] of body weight, PO, q 24 h); the other 4 received a placebo. Prostatic diameter, measured radiographically, prostatic volume, measured ultrasonographically, semen quality, and serum DHT and testosterone concentrations were evaluated before and during treatment. After receiving the placebo for 16 weeks, the 4 control dogs were treated with finasteride for 16 weeks, and evaluations were repeated. Results - Finasteride significantly decreased prostatic diameter (mean percentage decrease, 20%), prostatic volume (mean percentage decrease, 43%), and serum DHT concentration (mean percentage decrease, 58%). Finasteride decreased semen volume but did not adversely effect semen quality or serum testosterone concentration. No adverse effects were reported by owners of dogs in the study. Conclusions and Clinical Relevance - Results suggest that finasteride can be used to reduce prostatic size in dogs with BPH without adversely affecting semen quality or serum testosterone concentration.

AB - Objective - To determine the effect of the 5α-reductase inhibitor finasteride on prostatic diameter and volume, semen quality, and serum dihydrotestosterone (DHT) and testosterone concentrations in dogs with spontaneous benign prostatic hypertrophy (BPH). Design - Double-blind placebo-controlled trial. Animals - 9 dogs with BPH. Procedure - Five dogs were treated with finasteride for 16 weeks (0.1 to 0.5 mg/kg [0.05 to 0.23 mg/lb] of body weight, PO, q 24 h); the other 4 received a placebo. Prostatic diameter, measured radiographically, prostatic volume, measured ultrasonographically, semen quality, and serum DHT and testosterone concentrations were evaluated before and during treatment. After receiving the placebo for 16 weeks, the 4 control dogs were treated with finasteride for 16 weeks, and evaluations were repeated. Results - Finasteride significantly decreased prostatic diameter (mean percentage decrease, 20%), prostatic volume (mean percentage decrease, 43%), and serum DHT concentration (mean percentage decrease, 58%). Finasteride decreased semen volume but did not adversely effect semen quality or serum testosterone concentration. No adverse effects were reported by owners of dogs in the study. Conclusions and Clinical Relevance - Results suggest that finasteride can be used to reduce prostatic size in dogs with BPH without adversely affecting semen quality or serum testosterone concentration.

UR - http://www.scopus.com/inward/record.url?scp=0035871296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035871296&partnerID=8YFLogxK

U2 - 10.2460/javma.2001.218.1275

DO - 10.2460/javma.2001.218.1275

M3 - Article

C2 - 11330612

AN - SCOPUS:0035871296

VL - 218

SP - 1275

EP - 1280

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 8

ER -